Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.28, read 2026-11-03
Ethical does not pass the values gate
Price19.47 USD
Fair value18.45
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-21Read Accumulation14.78+31.7% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown14.44+34.8% to today Accumulation gives way to Markdown after a 21% slide in 6 weeks
2026-08-23Read Accumulation18.35+6.1% to today ✓Markup gives way to Accumulation after a 34% rise in 7 weeks
2026-07-02Read Markup13.73+41.8% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Bob's Discount Furniture, Inc. holds its Accumulation at $19.47. The statistical read favours the sellers, held for 75 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 75 days
Price at the screen
$19.47
Valuation
18.15 trailing · 17.41 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
65.02%
Below 33%
Interest-bearing debt is 65.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
3.91%
Below 49%
Money owed to the company is 3.9% of assets, under the 49% limit.
Pass
Revenue purity
0.09%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Bob's Discount Furniture,'s business is in a permissible area, but its interest-bearing debt is about 65% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BOBS's ethical verdict changes
Today BOBS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 1% discount to our $18.45 fair value, 8.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 5.5% above the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +13% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $18.45, with a range of $16.20 to $21.22, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Furniture sales swing with every housing cycle
Walk into any home store and you see sofas bought only when pay packets feel secure and houses are changing hands. Bob's Discount Furniture sits right in that cycle, with revenue up just 8 percent and margins stuck at 5 percent. The shares trade at 15 times forward earnings below our calculated value, yet the opportunity rating stays at none because the business offers no durable edge.
Thirteen analysts call it a buy with a 22 dollar median target, and the ethical screen clears without issue. Still the unknown moat and thin profitability leave little cushion once spending slows. A low multiple on a cyclical name often signals peak earnings rather than a bargain.
Housing data and consumer confidence can turn quickly, cutting demand and exposing the lack of pricing power. That combination keeps us on the sidelines despite the apparent discount. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BOBS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Accumulation$18.33+7.6%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Accumulation$17.04+2.8%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$16.57+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$16.57+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$16.57+3.8%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$15.96+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$15.96+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$15.96+5.8%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$15.08+2.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $22.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.